Pipeline
Today, our drug candidates are focused on treating rare, genetic metabolic diseases, with other major diseases on the horizon.
Synlogic is currently developing medicines that address disease from a base of operation in the gut microbiome or from within a tumor, using our proprietary approach to creating living Synthetic BioticTM medicines.
- Our proprietary pipeline includes Synthetic Biotic medicines that are being evaluated in clinical trials for the treatment of phenylketonuria (PKU) and hyperammonemia, and an oncology program in IND-enabling studies.
- In collaboration with partners, we will apply our proprietary platform to create innovative Synthetic Biotic medicines for the treatment of major diseases in disease areas including inflammation, metabolism, oncology and CNS.
.
.